TY - JOUR
T1 - Diseño, desarrollo y evaluación preclínica de SOBERANA®02
T2 - Una vacuna cubana contra COVID-19
AU - Balbín, Yury Valdés
AU - Mederos, Darielys Santana
AU - Moreno, Lauren María Quintero
AU - Castillo, Sonsire Fernández
AU - Noda, Laura Marta Rodríguez
AU - Ramírez, Belinda S. nchez
AU - Nicado, Rocmira P. rez
AU - Grogues, Claudia Ofelia Acosta
AU - Gómez, Yanira M. ndez
AU - Ricardo, Manuel García
AU - García, Tays Hernández
AU - Báez, Gretchen Bergado
AU - Estopiñán, Franciscary Pi
AU - Zayas, Anet Valdés
AU - Portilla, Tania Carmenate
AU - González, Ubel Jesús Ramírez
AU - Hernández, Reynaldo Oliva
AU - Mora, Jean Pierre Soubal
AU - Arteaga, Raine Garrido
AU - Jorge, F. lix Cardoso San
AU - Cuervo, Mario Landys Chovel
AU - Rodríguez, Humberto González
AU - Medina, Mildrey Fariñas
AU - Salazar, Tamara Hernández
AU - Enríquez Puertas, Juliet M.
AU - Romero, Enrique Noa
AU - Batista, Anamary Suárez
AU - Fang, Cheng
AU - Rodríguez, Luis Ariel Espinosa
AU - Gómez, Yassel Ramos
AU - López, Luis Javier González
AU - Ruiz, Yanet Climent
AU - Dorantes, Gertrudis Rojas
AU - Hernández, Ernesto Relova
AU - Infante, Yanelys Cabrera
AU - Chang, Sum Lai Lozada
AU - Ayo, Tammy Boggiano
AU - Magaz, Eduardo Ojito
AU - Monzón, Kalet León
AU - Chiodo, Fabrizio
AU - Paquet, Françoise
AU - Chen, Guang-Wu
AU - Serra, Lila Rosa Castellanos
AU - Rivera, Daniel García
AU - Rivera, Dagmar García
AU - Bencomo, Vicente Guillermo Verez
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Introduction: Controlling the global COVID-19 pandemic depends, among other measures, on developing preventive vaccines against SARS-CoV-2. Virus infection is mediated by the interaction of the spike glycoprotein trimer, via its receptor binding domain (RBD), with the host’s cellular receptor. Vaccines in use or under development seek to elicit neutralizing antibodies to block virus binding to ACE2 receptor. Antibody response to this domain is an important outcome of immunization and correlates well with viral neutralization. Methods: The development and preclinical evaluation of SOBERANA®02 was carried out in four fundamental stages: 1) immunogen design, 2) obtaining the RBD viral antigen by recombinant technique, 3) obtaining and characterizing RBDn-TT conjugates, and 4) evaluation of conjugates immunogenicity in laboratory animals. Results and discussion: Here we show that macromolecular constructs with recombinant RBD conjugated to tetanus toxoid (TT) induce a potent immune response in laboratory animals. Some advantages of immunization with RBD-TT conjugates include a predominant anti-RBD IgG immune response due to affinity maturation and long-term specific B-memory cells. Conclusions. This result demonstrated the potential of this COVID-19 conjugate vaccine candidate and enabled its advance to clinical evaluation, paving the way for other antiviral conjugate vaccines.
AB - Introduction: Controlling the global COVID-19 pandemic depends, among other measures, on developing preventive vaccines against SARS-CoV-2. Virus infection is mediated by the interaction of the spike glycoprotein trimer, via its receptor binding domain (RBD), with the host’s cellular receptor. Vaccines in use or under development seek to elicit neutralizing antibodies to block virus binding to ACE2 receptor. Antibody response to this domain is an important outcome of immunization and correlates well with viral neutralization. Methods: The development and preclinical evaluation of SOBERANA®02 was carried out in four fundamental stages: 1) immunogen design, 2) obtaining the RBD viral antigen by recombinant technique, 3) obtaining and characterizing RBDn-TT conjugates, and 4) evaluation of conjugates immunogenicity in laboratory animals. Results and discussion: Here we show that macromolecular constructs with recombinant RBD conjugated to tetanus toxoid (TT) induce a potent immune response in laboratory animals. Some advantages of immunization with RBD-TT conjugates include a predominant anti-RBD IgG immune response due to affinity maturation and long-term specific B-memory cells. Conclusions. This result demonstrated the potential of this COVID-19 conjugate vaccine candidate and enabled its advance to clinical evaluation, paving the way for other antiviral conjugate vaccines.
UR - https://www.scopus.com/pages/publications/85198406407
M3 - Article
SN - 2304-0106
VL - 13
JO - Anales de la Academia de Ciencias de Cuba
JF - Anales de la Academia de Ciencias de Cuba
IS - 1
M1 - e1401
ER -
SDG 3 Good Health and Well-being